Critical Comparison: Jasper Therapeutics (NASDAQ:JSPR) versus Evaxion Biotech A/S (NASDAQ:EVAX)

Jasper Therapeutics (NASDAQ:JSPR) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Profitability

This table compares Jasper Therapeutics and Evaxion Biotech A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-63.21%	-55.07%
Evaxion Biotech A/S	N/A	-451.63%	-149.27%

Analyst Recommendations

This is a breakdown of current recommendations for Jasper Therapeutics and Evaxion Biotech A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	0	0	8	0	3.00
Evaxion Biotech A/S	0	0	2	0	3.00

Jasper Therapeutics currently has a consensus price target of $64.17, suggesting a potential upside of 165.48%. Evaxion Biotech A/S has a consensus price target of $11.00, suggesting a potential upside of 172.28%. Given Evaxion Biotech A/S’s higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Jasper Therapeutics.

Institutional & Insider Ownership

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Jasper Therapeutics and Evaxion Biotech A/S’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$64.46 million	($6.20)	-3.90
Evaxion Biotech A/S	$70,000.00	301.27	-$22.12 million	($6.76)	-0.60

Evaxion Biotech A/S has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Jasper Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.

Summary

Jasper Therapeutics beats Evaxion Biotech A/S on 6 of the 11 factors compared between the two stocks.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.